文献速递血脂与心血管预防

人工智能在心血管药物治疗中的应用与前景

Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives.
PubMed 文献 · Eur Heart J · 2025-01-01

本文系统综述了人工智能(AI)在心血管药物治疗中的应用现状,包括利用机器学习和计算机模拟优化药物选择、预测疗效与不良反应、识别获益人群、加速药物研发、检测药物相互作用及辅助临床试验设计。文章指出,AI 应用需在多样化人群中验证,并解决数据质量、隐私和偏倚问题,科学学会与监管机构应建立标准化框架以促进安全有效的临床整合。

要点

  • AI 可优化心血管药物选择、预测疗效与不良反应,辅助个体化治疗。
  • AI 有助于识别治疗获益人群、加速药物研发并提高临床试验效率。
  • 临床应用前需跨人群验证,并解决数据质量、隐私与偏倚问题。

核心结论

  • AI 在心血管药物治疗中具有改善患者结局的潜力,但需稳健验证和标准化框架支持临床整合。

研究设计与样本

  • 本文为系统综述,回顾 AI 在心血管药物治疗中的应用现状与前景。

主要发现

  • 机器学习和计算机模拟可识别可能从特定治疗中获益的人群、加速新药发现并降低成本。
  • 计算方法可促进药物相互作用检测,并基于真实世界数据定制干预以支持个性化照护。
  • AI 方法在利用患者反应实时数据优化临床试验设计与执行、提高招募效率方面展现前景。

临床怎么用

  • 可利用 AI 辅助心血管药物选择、疗效与不良反应预测及药物相互作用检测。
  • 在临床采用 AI 工具前,需确保其在多样化患者群体中得到验证并关注数据质量与偏倚。

局限性

  • 需在多样化患者群体中进行稳健验证以确保准确性和普适性。
  • 需解决数据质量、隐私和偏倚问题,避免加剧医疗差距。
  • 科学学会和监管机构尚需建立数据管理、模型认证和透明度的标准化框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in artificial intelligence (AI) have shown great potential in improving cardiovascular pharmacotherapy by optimizing drug selection, predicting therapeutic efficacy and adverse effects, ultimately improving patient outcomes. Leveraging techniques like machine learning and in silico modelling, AI can identify populations likely to benefit from specific treatments, expedite novel drug discovery and reduce costs. Computational methods can also facilitate the detection of drug interactions and tailor interventions based on real-world data, supporting personalized care. Artificial intelligence-based approaches also show promise in streamlining clinical trial design and execution, leveraging on real-time data on patient responsiveness, enhancing recruitment efficiency. However, in order to fully realize these benefits, robust validation across diverse patient populations is necessary to ensure accuracy and generalizability. In addition, addressing concerns regarding data quality, privacy, and bias is equally critical to avoid exacerbating existing healthcare disparities. Scientific societies and regulatory agencies must ultimately establish standardized frameworks for data management, model certification, and transparency, to enable safe and effective integration of AI into clinical practice. This manuscript aims at systematically reviewing the current state-of-the-art applications of AI in cardiovascular pharmacotherapy, describing their current potential in guiding treatment decisions, refine trial methodologies and support drug discovery.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Costa F, Gomez Doblas JJ, Díaz Expósito A, et al. Artificial intelligence in cardiovascular pharmacotherapy: applications and perspectives. Eur Heart J. 2025. PMID: 40662528. doi:10.1093/eurheartj/ehaf474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。